351 related articles for article (PubMed ID: 21605997)
41. Leishmanicidal evaluation of extracts from native plants of the Yucatan peninsula.
Peraza-Sánchez SR; Cen-Pacheco F; Noh-Chimal A; May-Pat F; Simá-Polanco P; Dumonteil E; García-Miss MR; Mut-Martín M
Fitoterapia; 2007 Jun; 78(4):315-8. PubMed ID: 17482379
[TBL] [Abstract][Full Text] [Related]
42. Biological and chemical studies of Pera benensis, a Bolivian plant used in folk medicine as a treatment of cutaneous leishmaniasis.
Fournet A; Angelo A; Muñoz V; Roblot F; Hocquemiller R; Cavé A
J Ethnopharmacol; 1992 Sep; 37(2):159-64. PubMed ID: 1434690
[TBL] [Abstract][Full Text] [Related]
43. Experimental treatment of cutaneous leishmaniasis with argentilactone isolated from Annona haematantha.
Waechter AI; Ferreira ME; Fournet A; Rojas de Arias A; Nakayama H; Torres S; Hocquemiller R; Cavé A
Planta Med; 1997 Oct; 63(5):433-5. PubMed ID: 9342948
[TBL] [Abstract][Full Text] [Related]
44. In vivo efficacy of oral and intraperitoneal administration of extracts of Warburgia ugandensis (Canellaceae) in experimental treatment of Old World cutaneous leishmaniasis caused by Leishmania major.
Ngure PK; Ng'ang'a Z; Ingonga J; Rukunga G; Tonui WK
Afr J Tradit Complement Altern Med; 2009 Mar; 6(2):207-12. PubMed ID: 20209014
[TBL] [Abstract][Full Text] [Related]
45. Antimicrobial peptides for leishmaniasis.
Cobb SL; Denny PW
Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
[TBL] [Abstract][Full Text] [Related]
46. Antileishmanial activity of some plants growing in Algeria: Juglans regia, Lawsonia inermis and Salvia officinalis.
Serakta M; Djerrou Z; Mansour-Djaalab H; Kahlouche-Riachi F; Hamimed S; Trifa W; Belkhiri A; Edikra N; Hamdi Pacha Y
Afr J Tradit Complement Altern Med; 2013; 10(3):427-30. PubMed ID: 24146470
[TBL] [Abstract][Full Text] [Related]
47. Arsenite resistance in Leishmania and possible drug targets.
Singh G; Jayanarayan KG; Dey CS
Adv Exp Med Biol; 2008; 625():1-8. PubMed ID: 18365654
[TBL] [Abstract][Full Text] [Related]
48. Antileishmanial activity of a tetralone isolated from Ampelocera edentula, a Bolivian plant used as a treatment for cutaneous leishmaniasis.
Fournet A; Barrios AA; Muñoz V; Hocquemiller R; Roblot F; Cavé A
Planta Med; 1994 Feb; 60(1):8-12. PubMed ID: 8134421
[TBL] [Abstract][Full Text] [Related]
49. Discovery of Alternative Chemotherapy Options for Leishmaniasis through Computational Studies of Asteraceae.
Herrera-Acevedo C; Perdomo-Madrigal C; Muratov EN; Scotti L; Scotti MT
ChemMedChem; 2021 Apr; 16(8):1234-1245. PubMed ID: 33336460
[TBL] [Abstract][Full Text] [Related]
50. Recent researches in effective antileishmanial herbal compounds: narrative review.
Ghodsian S; Taghipour N; Deravi N; Behniafar H; Lasjerdi Z
Parasitol Res; 2020 Dec; 119(12):3929-3946. PubMed ID: 32803335
[TBL] [Abstract][Full Text] [Related]
51. In vitro activity of Tridax procumbens against promastigotes of Leishmania mexicana.
Martín-Quintal Z; Moo-Puc R; González-Salazar F; Chan-Bacab MJ; Torres-Tapia LW; Peraza-Sánchez SR
J Ethnopharmacol; 2009 Apr; 122(3):463-7. PubMed ID: 19429313
[TBL] [Abstract][Full Text] [Related]
52. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
[TBL] [Abstract][Full Text] [Related]
53. Plants as Antileishmanial Agents: Current Scenario.
Ullah N; Nadhman A; Siddiq S; Mehwish S; Islam A; Jafri L; Hamayun M
Phytother Res; 2016 Dec; 30(12):1905-1925. PubMed ID: 27704633
[TBL] [Abstract][Full Text] [Related]
54. Recent advances in antileishmanial drug development.
Davis AJ; Kedzierski L
Curr Opin Investig Drugs; 2005 Feb; 6(2):163-9. PubMed ID: 15751739
[TBL] [Abstract][Full Text] [Related]
55. Protease inhibitors in potential drug development for Leishmaniasis.
Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
[TBL] [Abstract][Full Text] [Related]
56. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics.
Kumari S; Kumar A; Samant M; Singh N; Dube A
Curr Drug Targets; 2008 Nov; 9(11):938-47. PubMed ID: 18991606
[TBL] [Abstract][Full Text] [Related]
57. Exploration of Antileishmanial Compounds Derived from Natural Sources.
Peer GDG; Priyadarshini A; Gupta A; Vibhuti A; Raj VS; Chang CM; Pandey RP
Antiinflamm Antiallergy Agents Med Chem; 2024; 23(1):1-13. PubMed ID: 38279725
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of synthetic substituted 1,2-dioxanes as novel agents against human leishmaniasis.
Ortalli M; Varani S; Rosso C; Quintavalla A; Lombardo M; Trombini C
Eur J Med Chem; 2019 May; 170():126-140. PubMed ID: 30878827
[TBL] [Abstract][Full Text] [Related]
59. [Old-World cutaneous leishmaniasis: an ancient disease in wait of new drugs].
Solomon M; Trau H; Schwartz E
Ann Dermatol Venereol; 2008 May; 135(5):357-9. PubMed ID: 18457720
[No Abstract] [Full Text] [Related]
60. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents.
Werbovetz K
Curr Opin Investig Drugs; 2006 Feb; 7(2):147-57. PubMed ID: 16499285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
